Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Adial Pharmaceuticals ( (ADIL) ) just unveiled an update.
On May 23, 2025, Adial Pharmaceuticals received a letter from Nasdaq indicating non-compliance with certain listing rules due to insufficient stockholders’ equity and market value. To address this, the company conducted a best efforts offering on June 18, 2025, raising approximately $3.6 million. As a result, Adial believes it has regained compliance with Nasdaq’s equity requirements, confirmed by a letter from Nasdaq on July 14, 2025. However, Nasdaq will continue to monitor the company’s compliance, with potential delisting if future reports show non-compliance.
The most recent analyst rating on (ADIL) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Adial Pharmaceuticals stock, see the ADIL Stock Forecast page.
Spark’s Take on ADIL Stock
According to Spark, TipRanks’ AI Analyst, ADIL is a Underperform.
Adial Pharmaceuticals’ overall stock score is low due to ongoing financial struggles, including a lack of revenue and reliance on external funding. Technical analysis provides no strong directional signal, and valuation metrics are weak due to negative earnings. However, the recent FDA approval for AD04 offers a positive strategic outlook, but this is not enough to counteract the financial and operational challenges currently faced.
To see Spark’s full report on ADIL stock, click here.
More about Adial Pharmaceuticals
Adial Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing treatments for addiction and related disorders.
Average Trading Volume: 8,337,983
Technical Sentiment Signal: Sell
Current Market Cap: $5.82M
For an in-depth examination of ADIL stock, go to TipRanks’ Overview page.